Back to News
Market Impact: 0.2
ImmuPharm Posts Wider H1 Loss As Pipeline Progresses Toward Clinical Studies; Stock Down
Source: Nasdaq
Healthcare & BiotechCorporate EarningsCompany Fundamentals
ImmuPharm reported interim results for the six months ended June 30, 2026, with its half-year loss widening. The increase in loss was attributed to a change in the fair value of a specific asset, rather than an operational metric disclosed in the report excerpt.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
More News
- Trump called out Big Oil profits. Here’s how much their refining earnings have surged since
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Wall Street Punishes Tech Stocks on Earnings Misses
- Reddit stock plunges 30% after weak outlook, heads for worst day ever
- Binance’s $6.3 Billion Cyber Heist Shows Crypto Vulnerabilities
- Intel’s stock crashes, knocking $12B from government’s stake